Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents with HIV-1 in IMPAACT P1093 and IMPAACT 2019.

2026

https://researcherprofiles.org/profile/822296648

42731017

McKenna M, Lulic Z, Buchanan AM, Brothers C, Tan LK, Wang M, Brummel S, Ziemba L, Ruel T, Flynn PM, Rabie H, Wiznia A